The GLP-1 Receptor Agonist Market is Trending by the Rising Prevalence of Diabetes
The GLP-1 receptor agonists market includes drugs that help in controlling blood glucose levels by stimulating the secretion of insulin from the pancreas. These drugs mimic the effects of the natural hormone glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonists provide effective glycemic control along with the benefit of weight loss by promoting satiety and delayed gastric emptying. The growing prevalence of type 2 diabetes combined with the rising adoption of GLP-1 receptor agonists as an alternative to insulin is promoting the growth of this market substantially.
Global GLP-1 receptor agonist market is estimated to be valued at USD 25.10 Bn in 2024 and is expected to reach USD 55.70 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.
Key players operating in the GLP-1 Receptor Agonist market are Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, GlaxoSmithKline. Novo Nordisk's Victoza (liraglutide) is the most prescribed GLP-1 receptor agonist drug globally. Eli Lilly's Trulicity (dulaglutide) also captures a sizable market share. The rising prevalence of diabetes, growing awareness about the therapeutic benefits of GLP-1 receptor agonists, and increasing obesity rates are fueling demand in the GLP-1 receptor agonist market substantially.
The GLP-1 Receptor Agonist Market Size agonist drugs is growing steadily owing to a rising number of patients with type 2 diabetes worldwide. As per estimations, around 537 million people suffered from diabetes in 2021 globally and the number is projected to rise to 10% of the world's adult population by 2030 and 78 million in the United States. GLP-1 receptor agonists present an effective alternative for glycemic control with the additional benefit of weight loss making them an attractive option, especially for obese diabetic patients.
Major pharmaceutical companies are focusing on geographical expansion to leverage market opportunities. For instance, Novo Nordisk launched Victoza in China in 2011 and has since strengthened its presence in key emerging markets. Eli Lilly also expanded the commercial availability of Trulicity to more than 50 countries. The rising investments in emerging economies by key players will further aid the global expansion of the GLP-1 receptor agonist market during the forecast period.
Market key trends in the GLP-1 receptor agonist segment include the development of once-weekly formulations. Cu
The GLP-1 receptor agonists market includes drugs that help in controlling blood glucose levels by stimulating the secretion of insulin from the pancreas. These drugs mimic the effects of the natural hormone glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonists provide effective glycemic control along with the benefit of weight loss by promoting satiety and delayed gastric emptying. The growing prevalence of type 2 diabetes combined with the rising adoption of GLP-1 receptor agonists as an alternative to insulin is promoting the growth of this market substantially.
Global GLP-1 receptor agonist market is estimated to be valued at USD 25.10 Bn in 2024 and is expected to reach USD 55.70 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.
Key players operating in the GLP-1 Receptor Agonist market are Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, GlaxoSmithKline. Novo Nordisk's Victoza (liraglutide) is the most prescribed GLP-1 receptor agonist drug globally. Eli Lilly's Trulicity (dulaglutide) also captures a sizable market share. The rising prevalence of diabetes, growing awareness about the therapeutic benefits of GLP-1 receptor agonists, and increasing obesity rates are fueling demand in the GLP-1 receptor agonist market substantially.
The GLP-1 Receptor Agonist Market Size agonist drugs is growing steadily owing to a rising number of patients with type 2 diabetes worldwide. As per estimations, around 537 million people suffered from diabetes in 2021 globally and the number is projected to rise to 10% of the world's adult population by 2030 and 78 million in the United States. GLP-1 receptor agonists present an effective alternative for glycemic control with the additional benefit of weight loss making them an attractive option, especially for obese diabetic patients.
Major pharmaceutical companies are focusing on geographical expansion to leverage market opportunities. For instance, Novo Nordisk launched Victoza in China in 2011 and has since strengthened its presence in key emerging markets. Eli Lilly also expanded the commercial availability of Trulicity to more than 50 countries. The rising investments in emerging economies by key players will further aid the global expansion of the GLP-1 receptor agonist market during the forecast period.
Market key trends in the GLP-1 receptor agonist segment include the development of once-weekly formulations. Cu
8 hours ago
